SCHEMBL3017811

SCHEMBL3017811

Cc1cc(C)cc(Cc2csc(N3CCC(S(=O)(=O)c4cc(Cl)ccc4Cl)CC3)n2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
HTT P42858 1/20 0.36
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 2/20 0.35
GAA P10253 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
RECQL P46063 1/20 0.35
ALOX15 P16050 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
DNM1L O00429 2/20 0.34
ACHE P22303 1/20 0.34
CNR1 P21554 1/20 0.34
RAB9A P51151 1/20 0.34
PPARG P37231 1/20 0.34
PPARD Q03181 1/20 0.34
PPARA Q07869 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011591 0.93 ACHE (0.36) TSHRNPSR1HTTMEN1POLB
SCHEMBL3018534 0.93 GAA (0.36) MAPTGAASMN1; SMN2DNM1LRAB9A
SCHEMBL3006085 0.92 GAA (0.38) TSHRNPSR1HTTMEN1POLB
SCHEMBL3018865 0.92 ALDH1A1 (0.39) TSHRNPSR1HTTMEN1POLB
SCHEMBL3012479 0.91 MAPT (0.39) TSHRNPSR1HTTPOLBKMT2A
SCHEMBL3015699 0.90 EPHX2 (0.35) TSHRNPSR1HTTMEN1POLB
SCHEMBL3013316 0.90 CTSS (0.41) MEN1KMT2ASMN1; SMN2DNM1LRAB9A
SCHEMBL3016285 0.89 MAPK1 (0.39) TSHRHTTPOLBKMT2AALDH1A1
SCHEMBL3013157 0.89 MAPT (0.36) TSHRNPSR1HTTMEN1POLB
SCHEMBL3009156 0.89 PTGDR2 (0.36) TSHRNPSR1HTTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TSHR 3320/4885NPSR1 764/4885HTT 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.